1-(4-Fluorophenyl)-1H-pyrazol-5-ylboronic acid → 6-[2-(4-Fluoro-phenyl)-2H-pyrazol-3-yl]-1-p-tolyl-1H-benzoimidazole
반응식
Br[C:2]1[CH:3]=[CH:4][C:5]2[N:9]=[CH:8][N:7]([C:10]3[CH:15]=[CH:14][C:13]([CH3:16])=[CH:12][CH:11]=3)[C:6]=2[CH:17]=1.[F:18][C:19]1[CH:24]=[CH:23][C:22]([N:25]2[C:29](B(O)O)=[CH:28][CH:27]=[N:26]2)=[CH:21][CH:20]=1>>[F:18][C:19]1[CH:20]=[CH:21][C:22]([N:25]2[C:29]([C:2]3[CH:3]=[CH:4][C:5]4[N:9]=[CH:8][N:7]([C:10]5[CH:15]=[CH:14][C:13]([CH3:16])=[CH:12][CH:11]=5)[C:6]=4[CH:17]=3)=[CH:28][CH:27]=[N:26]2)=[CH:23][CH:24]=1참가 물질
3
실험 절차
The title compound, off-white solid (22 mg, 17%), MS (ISP) m/z=369.2 [(M+H)+], mp 149° C., was prepared in accordance with the general method of example 1 from 6-bromo-1-p-tolyl-1H-benzo[d]imidazole (intermediate F) (100 mg, 348 μmol) and 1-(4-fluoro-phenyl)-1H-pyrazol-5-ylboronic acid (intermediate A) (93.3 mg, 453 μmol).
출처 및 근거
- ORD 기록
- ord-27ac262422e64887a1894e3f0a0f2f72
- 출처 데이터셋
- uspto-grants-2016_06
- DOI